The assistant professor of Medicine in the division of Hematology and Medical Oncology at Weill Cornell Medicine spoke about exciting research coming out of ASH for patients with chronic lymphocytic leukemia.
In an interview with CancerNetwork®, John N. Allan, MD, assistant professor of medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine, discussed the latest research coming out of the 62nd American Society of Hematology (ASH) Annual Meeting for patients with chronic lymphocytic leukemia (CLL).
Transcription:
Yeah, so one of the big things I'm most interested about this year's ASH is as when I was reviewing the abstracts was seeing, how much data is going to be emerging in terms of the combinations and really seeing how deep can these responses go? How durable are these responses after maximal therapy, so to speak, and stopping or fixed durations of therapies and so, so that'll be really important to keep an eye on. As well as, you know, we're getting better at understanding resistant mechanisms to these targeted agents, so, looking at how patients relapse, how do they respond to new therapies after they've relapsed, especially if they've had treatment holidays. So, these are things that will be at this year's ASH and looking forward to digesting that data.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.